SLC5A2 and hydrops fetalis: Given the effects of SGLT-2 inhibition on interstitial/plasma fluid volume [70] and BP [66, 71], a beneficial effect on cardiac pre-load and after-load is expected, and a reduction in the incidence of clinical outcomes among those with HF with reduced or preserved ejection fraction might be anticipated with such treatments [42].